






# IMMUNOMODULATORY ACTIVITY OF BENZNIDAZOLE (BZN) IN EHRLICH ASCITES CARCINOMA (EAC) IN SILICO AND IN VIVO

PhD. Rodrigo Costa Zeferino
Department of Pharmacy, Federal University of Santa Catarina, Florianópolis, Brazil
Universidade Federal de Santa Catarina

### Cancer

Cancer is a major global public health problem represented by around 10 million people killed in 2020 (WORLD HEALTH ORGANIZATION, 2023). Female breast cancer is the most prevalent in the world with (2.6 million) new cases, followed by lung cancer (2.21 million, third and colon and rectal cancer (1.93 million), fourth prostate with 7.3% (1.41 million), non-melanoma skin with 6.2% (1.2 million), and stomach (1.09 million), new cases in the world (WORLD HEALTH ORGANIZATION, 2023).



All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization / International Agency for Research on Cancer concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate borderlines for which there may not yet be full agreement.

Data source: GLOBOCAN 2020 Map production: IARC (http://gco.iarc.fr/today) World Health Organization



#### Cancer


In Brazil, the estimate for the 2023-2025 triennium indicates 704 thousand new cases of cancer, that is, 483 thousand excluding cases of non-melanoma skin cancer. For these numbers, an estimated 10.5% of female breast cancers (74 thousand), prostate with 10.2% (72 thousand), colon and rectum with 6.5% (46 thousand), lung cancer with 4.6% (32 thousand), with 31.3% (220 thousand), non-melanoma skin cancer, and 3.1% and (21 thousand), for stomach cancer (INSTITUTO NATIONAL DE CANCER – INCA Estimate 2023, 2023).






Brazil brasilescola.uol.com.br

In cancer, there is a loss of control over the mechanisms of proliferation, differentiation and cell death (Moffat et al., 2000; Hanahan; Weinberg, 2011).




Siddiqui, I.A., Sanna, V. et al (2015)



https://www.aacr.org/blog/2022/01/21/new-dimensions-in-cancer-biology-updated-hallmarks-of-cancer-published/


# BENZNIDAZOLE - BZN

N-benzyl-2-(2-nitroimidazol-1-yl) acetamide




Reactive Metabolite
Prodrug – activation by CYP 450

#### **BZN**



American trypanosomiasis, called Chagas disease in honor of its discoverer, Brazilian researcher Carlos Chagas, is an important parasitic disease resulting from infection by the hemoflagellate protozoan parasite Trypanosoma cruzi, with triatomine insects as vectors



Trypanosoma cruzi
https://www.icc.fiocruz.br/doenca-de-chagas/




https://revistapesquisa.fapesp.br/focosde-barbeiro-na-cidade-de-sao-paulo/



Carlos Chagas 1878 -1934

### **BENZNIDAZOLE -BZN**

N-benzyl-2-(2-nitroimidazol-1-yl) acetamide





- → BZN came into medical in 1971 year.
  - → Knowledge acquired through 50 years of use

Reactive Metabolite
Prodrug – activation by CYP 450

"The free racidals produced act on DNA, proteins and lipids leading to importante Oxidative damage to biological macromolecules" (URBINA; DO CAMPO, 2003)"

# Therefore...





Células Tumor Ascítico de Ehrlich

# Tumor cells and parasites exhibit metabolic similarities

- → Uneven antioxidant defense
  - → High proliferation
- → Evasion of the immune response.

(M.Q. KLINKERT, V. HEUSSLER, 2006)

We used PASS software to predict the interaction of BZN (PubChem Cid: 31593), with molecular target groups

# **Molecular Target Group**

| TARGET                | NUMBER OS TARGETS ASSOCIATED WITH |  |  |
|-----------------------|-----------------------------------|--|--|
|                       | GO BIOLOGICAL PROCESSES           |  |  |
| RESPONSE TO STRESS    | 40                                |  |  |
| SIGNAL TRANSDUCTION   | 55                                |  |  |
| METABOLIC PROCESS     | 35                                |  |  |
| IMMUNE SYSTEM PROCESS | 27                                |  |  |

We used PASS software to predict the interaction of BZN (PubChem Cid: 31593), with possible biological activities

# Predict possible biological activities

| Pa    | $P_{i}$ | Activity                                     |
|-------|---------|--|
| 0.888 | 0.001   | Chemosensitizer                              |
| 0.827 | 0.002   | Radiosensitizer                              |
| 0.633 | 0.003   | Oxidizing agent                              |
| 0.409 | 0.008   | Antineoplastic enhancer                      |
| 0.409 | 0.015   | Antioplastic (Pancreatic cancer)             |
| 0.482 | 0.093   | Calcium channel (voltage-sensitive)activator |
| 0.404 | 0.036   | Antineoplastic (solid Tumors)                |

# These results corroborate with Zeferino et al., 2019, which demonstrate the ability of BZN to inhibit tumor growth, generating reactive oxygen species, increasing calcium influx, activating apoptosis

Investigational New Drugs (2020) 38:785–799 https://doi.org/10.1007/s10637-019-00820-5


#### PHASE I STUDIES



Targeting ROS overgeneration by N-benzyl-2-nitro-1-imidazole-acetamide as a potential therapeutic reposition approach for cancer therapy

Rodrigo C. Zeferino<sup>1</sup> · Nádia S. R. S. Mota<sup>1</sup> · Valdelúcia M. A. S. Grinevicius<sup>1</sup> · Karina B. Filipe<sup>2</sup> · Paola M. Sulis<sup>1</sup> · Fátima R. M. B. Silva<sup>1</sup> · Danilo W. Filho<sup>3</sup> · Claus T. Pich<sup>4</sup> · Rozangela C. Pedrosa<sup>1</sup>

### Design of experiments in vivo




# It's important to remember that.....


EAC has low expression of histocompatibility complex proteins, demonstrating that cellular immunity is not the main mechanism of host reaction against this tumor (CHEN, L. WATKINS, J.F. 1970).

| Cells (%) | EAC cells  | Neutrophils |           | Lymphocyte | Monocyte  |
|-----------|------------|-------------|-----------|------------|-----------|
|           |            | Segmented   | Band      |            |           |
| Control   | 97.50±1.00 | 1.25±0.50   | 0.25±0.30 | 0.33±0.57  | 1.00±0.57 |
| MTX       | 97.30±0.56 | ND          | ND        | ND         | ND        |
| BZN       | 92.50±0.57 | 5.35±1.25   | 1.75±0.95 | 0.33±0.47  | 1.00±0.50 |

*Note:* Neutrophils = (Segmented + band)

# Increased infiltration of immune system cells in treated animals







| Cells (%) | EAC cells  | Neutrophils |           | Lymphocyte | Monocyte  |
|-----------|------------|-------------|-----------|------------|-----------|
|           |            | Segmented   | Band      |            |           |
| Control   | 97.50±1.00 | 1.25±0.50   | 0.25±0.30 | 0.33±0.57  | 1.00±0.57 |
| MTX       | 97.30±0.56 | ND          | ND        | ND         | ND        |
| BZN       | 92.50±0.57 | 5.35±1.25   | 1.75±0.95 | 0.33±0.47  | 1.00±0.50 |

*Note:* Neutrophils = (Segmented + band)

# 1 5-fold 7-fold Increased infiltration of immune system cells in treated animals






| Cells (%) | EAC cells  | Neutrophils            |           | Lymphocyte | Monocyte  |
|-----------|------------|------------------------|-----------|------------|-----------|
|           |            | Segmented              | Band      |            |           |
| Control   | 97.50±1.00 | 1.25±0.50              | 0.25±0.30 | 0.33±0.57  | 1.00±0.57 |
| MTX       | 97.30±0.56 | ND                     | ND        | ND         | ND        |
| BZN       | 92.50±0.57 | 5.35±1.25 <sup>a</sup> | 1.75±0.95 | 0.33±0.47  | 1.00±0.50 |


*Note:* Neutrophils = (Segmented + band)

### Increased infiltration of immune system cells in treated animals




Granot, Z.. Jablonska, J. (2015)

# Myeloperoxidase (MPO)



Quantification of immune cells present in ascites fluid collect from EAC bearing BALB-c mice male, n=6; 20±2g weight: The activity of myeloperoxidase (MPO) was attenuated after treatment with BZN 10mg/kg/day. (\*\*\*) denotes statistical difference when compared to controls (p<0.001). Values are expressed as means ± S.E.M, n=6.

# Myeloperoxidase (MPO)



Quantification of immune cells present in ascites fluid collect from EAC bearing BALB-c mice male, n=6; 20±2g weight: The activity of myeloperoxidase (MPO) was attenuated after treatment with BZN 10mg/kg/day. (\*\*\*) denotes statistical difference when compared to controls (p<0.001). Values are expressed as means ± S.E.M, n=6.

Studie published by Silva, E.L. et al. (1990), suggest that BZN can act as a modulator of the immune system, helping to eliminate Trypanosoma cruzi

Modulation of MPO appears to control the cytotoxic and immunoprotective activity mediated by defense cells (neutrophils), making the cytotoxic action more effective against tumor cells (CHANG, C.Y. et al. 2013)

Similar results were obtained by Lambertucci, F. (2017), who demonstrated the ability of BZN to attenuate the inflammatory response in murine sepsis models.

Therefore, the results demonstrate that BZN can act by modulating the immune system (Nuetrophils), facilitating the cytotoxic action of these cells against the tumor


# Conclusion

In view of the arguments presented, BZN presented important characteristics to be a possible promising candidate for the repositioning of drugs to combat tumor cells, however, we need more studies on its immunomodulation capacity.

# Acknowledgment











# Thank you very much for your attention

# References

World Health Organization - WHO. Cancer. Available in: <a href="https://www.who.int/health-topics/cancer#tab=tab\_1">https://www.who.int/health-topics/cancer#tab=tab\_1</a> . 17/09/2023

Instituto Nacional do Câncer - INCA. Estimativa incidência de câncer 2018 (a). Available in: https://www.inca.gov.br/publicacoes/livros/estimativa-2023-incidencia-de-cancer-no-brasil. 17/09/2023

Moffat, J., Hashimoto, M. et al (2000) Carcinogenisis, 21, 12.

Hanahan, D., Weinberg, R.A. (2011) Cell, 5, 674.

Siddiqui, I.A., Sanna, V. et al (2015) Annals of the New York Academy of Sciences, 1348, 31

Granot, Z., Jabloska, J. (2015) Mediators inflammation, 1, 11.

Urbina, J.A., Do Campo, R. (2003) Trends Parasitology, 11, 501.

# References

Klinkert M.Q, Heussler V. (2006) Mini-Reviews in Medicinal Chemistry. 2, 131-43.

Filimonov, D.A., Lagunin, A.A.et al (2014) Chemistry of Heterocyclic Compounds, 50, 457.

Pogodin, P.V., Lagunin, D.A. et al. (2015) SAR and QSAR in Environmental Research, 26, 793.

Zeferino, C. R.; Mota, N.S.R.S. et al (2019) Investigational New Drugs, 3, 799

Chen, L., Watkins, J. et al (1970) Nature. 225, 735.

Silva, E.L., Filardi, L.S. et al (1990) Memorial Instituto Oswaldo Cruz,4, 405.

Chang, C.Y., Choi, D. K. et al (2013) Plos One, 4, 13.

Lambertucci, F., Motino, O. et al (2017) *Toxicology Applied Pharmacology*, 15, 22.







# IMMUNOMODULATORY ACTIVITY OF BENZNIDAZOLE (BZN) IN EHRLICH ASCITES CARCINOMA (EAC) IN SILICO AND IN VIVO

PhD. Rodrigo Costa Zeferino
Department of Pharmacy, Federal University of Santa Catarina, Florianópolis, Brazil
Universidade Federal de Santa Catarina

